Stock Analiz

DarioHealth Corp. DRIO

Medical/Dental Instruments · data as of November 13, 2026

$1.26Market cap $14M
Open the interactive analysis →

DarioHealth Corp. (DRIO) is a healthcare company listed in the US with a market value of about $14M. In the twelve months to September 30, 2026 it had revenue of $21M and net income of -$34M, a net margin of -159.9%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 24% a year, a 5-year average ROIC of -49%.

About DarioHealth

DarioHealth is listed in the US and classified in medical/dental instruments. Revenue went from $51000 in 2014 to $22M in 2025, growth of about 73.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 237% over three years (dilution for shareholders). It spends 62% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.7
P/B0.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-166.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-17.3%
Revenue growth (5 yrs, per year)24.2%
EPS growth (5 yrs, per year)-33.9%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-247.1%
ROIC (5-yr avg.)-49.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$21M$22M$27M$20M$28M$21M$8M$8M$7M$5M$3M
Net income-$34M-$42M-$43M-$59M-$62M-$77M-$29M-$18M-$18M-$16M-$11M
Free cash flow-$24M-$26M-$39M-$31M-$48M-$51M-$18M-$16M-$12M-$11M-$9M
EPS (diluted)$-2.28$3.37$4.09$12.87$16.93$27.13$26.73$53.33$104.20$218.67$278.67
Net margin-159.9%-186.6%-158.1%-292.0%-224.9%-374.2%-388.7%-234.6%-240.8%-304.5%-388.4%
ROIC—-29.0%-54.1%-50.6%-41.5%-70.4%-82.4%-71.1%-156.6%-289.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $8.20, 551% above the current price; targets range from $5.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-2.46 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does DarioHealth pay a dividend?

Not currently.

Is DarioHealth a good stock to buy?

We do not give buy or sell advice. DarioHealth scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.